BioXcel Therapeutics Announced Overall Survival Data From Its Phase 2 Trial Of BXCL701 Plus Keytruda (Pembrolizumab) In Patients With Small Cell Neuroendocrine Prostate Cancer
Portfolio Pulse from Benzinga Newsdesk
BioXcel Therapeutics has announced overall survival data from its Phase 2 trial of BXCL701 plus Keytruda in patients with small cell neuroendocrine prostate cancer. The data shows a median overall survival of 13.6 months and a 12-month survival rate of 56.5%.
October 10, 2023 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioXcel Therapeutics' Phase 2 trial results for BXCL701 plus Keytruda in treating small cell neuroendocrine prostate cancer show promising survival rates, which could potentially boost the company's stock.
The positive results from the Phase 2 trial of BXCL701 plus Keytruda indicate a potential new treatment for small cell neuroendocrine prostate cancer. This could lead to increased revenues for BioXcel Therapeutics, which would likely have a positive impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100